Credit Suisse Group Analysts Give Regeneron Pharmaceuticals (NASDAQ:REGN) a $440.00 Price Target

Regeneron Pharmaceuticals (NASDAQ:REGN) received a $440.00 price target from investment analysts at Credit Suisse Group in a note issued to investors on Wednesday, February 7th. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target indicates a potential upside of 33.06% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. Cowen reiterated a “hold” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Canaccord Genuity reaffirmed a “buy” rating and issued a $522.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 7th. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Jefferies Group reiterated a “hold” rating and set a $421.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average price target of $463.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $6.12 during trading on Wednesday, hitting $330.69. 1,981,300 shares of the company were exchanged, compared to its average volume of 1,070,315. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals has a 52 week low of $313.53 and a 52 week high of $543.55. The firm has a market cap of $34,871.48, a P/E ratio of 32.13, a PEG ratio of 1.34 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s revenue was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.04 earnings per share. analysts anticipate that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.80% of the company’s stock.

Large investors have recently made changes to their positions in the stock. National Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 3.1% during the 2nd quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 26 shares during the period. Global X MANAGEMENT CO LLC raised its holdings in Regeneron Pharmaceuticals by 10.7% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 1,334 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 129 shares during the period. King Luther Capital Management Corp raised its holdings in Regeneron Pharmaceuticals by 21.3% during the 3rd quarter. King Luther Capital Management Corp now owns 825 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 145 shares during the period. Advantus Capital Management Inc raised its holdings in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Advantus Capital Management Inc now owns 7,885 shares of the biopharmaceutical company’s stock valued at $3,526,000 after buying an additional 148 shares during the period. Finally, BTIM Corp. raised its holdings in Regeneron Pharmaceuticals by 14.3% during the 4th quarter. BTIM Corp. now owns 1,200 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 150 shares during the period. Institutional investors own 65.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://weekherald.com/2018/02/15/regeneron-pharmaceuticals-regn-given-a-440-00-price-target-at-credit-suisse-group.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply